Skip to main content

Volume 3 Supplement 2

30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)

Discovery and characterization of an immunogenic neoantigen in a patient with metastatic triple negative breast cancer

A growing body of evidence suggests that successful clinical immunotherapy may depend on mutation-specific T cell responses. Using whole-exome and RNA sequencing of a resected metastatic deposit from a patient with triple-negative (ER-, PR-, Her2 non-amplified) breast cancer, we identified 72 non-synonymous mutations. Using previously published methods of autologous antigen presentation[1], we identified a novel non-synonymous mutation in a regulator of the Notch signaling pathway, RBPJ (recombination signal binding protein for immunoglobulin kappa J region), that encodes a neoantigen specifically recognized by autologous CD4+ tumor infiltrating lymphocytes. Antigen recognition was restricted by the Class II DR locus. Deep sequencing or PCR of all 16 metastases collected at autopsy revealed that the mutation was ubiquitously present in all samples. To the best of our knowledge, this represents the first report of an immunogenic mutation in breast cancer.

References

  1. 1.

    Tran E, Turcotte S, Gros A, et al: Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014, 344: 641-5.

    PubMed  CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Stephanie Goff.

Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.

The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Assadipour, Y., Goff, S., Crystal, J.S. et al. Discovery and characterization of an immunogenic neoantigen in a patient with metastatic triple negative breast cancer. j. immunotherapy cancer 3, P284 (2015). https://doi.org/10.1186/2051-1426-3-S2-P284

Download citation

Keywords

  • Breast Cancer
  • Notch Signaling
  • Triple Negative Breast Cancer
  • Tumor Infiltrate Lymphocyte
  • Notch Signaling Pathway